Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin, discusses impactful targeted therapies for patients with FLT3-mutant acute myeloid leukemia (AML).
Lyndsey Runaas, MD
Advertisement
Articles by Lyndsey Runaas, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5